200,000+ products from a single source!
sales@angenechem.com
53179-13-8 | 5-Methyl-1-phenyl-2(1H)-pyridinone
CAS No: 53179-13-8 Catalog No: AG0035HT MDL No:MFCD00866047
Product Description
Catalog Number:
AG0035HT
Chemical Name:
5-Methyl-1-phenyl-2(1H)-pyridinone
CAS Number:
53179-13-8
Molecular Formula:
C12H11NO
Molecular Weight:
185.2218
MDL Number:
MFCD00866047
IUPAC Name:
5-methyl-1-phenylpyridin-2-one
InChI:
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
InChI Key:
ISWRGOKTTBVCFA-UHFFFAOYSA-N
SMILES:
Cc1ccc(=O)n(c1)c1ccccc1
UNII:
D7NLD2JX7U
NSC Number:
748456
Properties
Complexity:
285
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
185.084g/mol
Formal Charge:
0
Heavy Atom Count:
14
Hydrogen Bond Acceptor Count:
1
Hydrogen Bond Donor Count:
0
Isotope Atom Count:
0
Molecular Weight:
185.226g/mol
Monoisotopic Mass:
185.084g/mol
Rotatable Bond Count:
1
Topological Polar Surface Area:
20.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
1.9
Literature
| Title | Journal |
|---|---|
| Pirfenidone protects against paraquat-induced lung injury and fibrosis in mice by modulation of inflammation, oxidative stress, and gene expression. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20180201 |
| The K-Ras effector p38γ MAPK confers intrinsic resistance to tyrosine kinase inhibitors by stimulating EGFR transcription and EGFR dephosphorylation. | The Journal of biological chemistry 20170908 |
| Human precision-cut liver slices as a model to test antifibrotic drugs in the early onset of liver fibrosis. | Toxicology in vitro : an international journal published in association with BIBRA 20160901 |
| Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. | European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20140716 |
| Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury. | The Journal of pharmacology and experimental therapeutics 20140601 |
| A new hope for idiopathic pulmonary fibrosis. | The New England journal of medicine 20140529 |
| A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. | The New England journal of medicine 20140529 |
| Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs. | Toxicology and applied pharmacology 20140115 |
| Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors. | European journal of pharmacology 20131115 |
| Chronic potentiation of cardiac L-type Ca(2+) channels by pirfenidone. | Cardiovascular research 20121101 |
| Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway. | Shock (Augusta, Ga.) 20121101 |
| Effects of an anti-transforming growth factor-β agent (pirfenidone) on strabismus surgery in rabbits. | Current eye research 20120901 |
| The big clinical trials in idiopathic pulmonary fibrosis. | Current opinion in pulmonary medicine 20120901 |
| Into the matrix: targeting fibroblasts in pulmonary fibrosis. | Current opinion in pulmonary medicine 20120901 |
| Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats. | Clinical toxicology (Philadelphia, Pa.) 20120901 |
| Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation? | The European respiratory journal 20120901 |
| Genotoxic evaluation of pirfenidone using erythrocyte rodent micronucleus assay. | Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120801 |
| 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. | Minerva medica 20120801 |
| Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection. | Transplantation 20120727 |
| Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. | The clinical respiratory journal 20120701 |
| Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis. | The clinical respiratory journal 20120701 |
| Re: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. | Annals of plastic surgery 20120701 |
| Update in diffuse parenchymal lung disease 2011. | American journal of respiratory and critical care medicine 20120701 |
| Clinical highlights from the 2011 ERS Congress in Amsterdam. | The European respiratory journal 20120601 |
| Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. | European respiratory review : an official journal of the European Respiratory Society 20120601 |
| Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. | European respiratory review : an official journal of the European Respiratory Society 20120601 |
| Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. | European respiratory review : an official journal of the European Respiratory Society 20120601 |
| Simultaneous determination of dextromethorphan and dextrophan in rat plasma by LC-MS/MS and its application to a pharmacokinetic study. | Die Pharmazie 20120601 |
| Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome. | The Medical clinics of North America 20120501 |
| p38γ mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription. | The Journal of biological chemistry 20120427 |
| Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction. | Archives of dermatological research 20120401 |
| Pirfenidone treatment of idiopathic pulmonary fibrosis. | Therapeutic advances in respiratory disease 20120401 |
| Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents. | Bioorganic & medicinal chemistry letters 20120315 |
| Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis. | European journal of pharmacology 20120305 |
| Management of idiopathic pulmonary fibrosis. | Clinics in chest medicine 20120301 |
| [Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment]. | Deutsche medizinische Wochenschrift (1946) 20120301 |
| Drugs of the future for Peyronie's disease. | Medical hypotheses 20120201 |
| Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones. | Molecules (Basel, Switzerland) 20120117 |
| A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. | Annals of plastic surgery 20120101 |
| The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice. | Hypertension research : official journal of the Japanese Society of Hypertension 20120101 |
| Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy. | PLoS pathogens 20120101 |
| [Chronic kidney disease, new therapeutic approaches]. | La Revue du praticien 20120101 |
| Smoking and idiopathic pulmonary fibrosis. | Pulmonary medicine 20120101 |
| Active roles of tumor stroma in breast cancer metastasis. | International journal of breast cancer 20120101 |
| Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. | Molecular vision 20120101 |
| Therapeutic potential of ginger against renal injury induced by carbon tetrachloride in rats. | TheScientificWorldJournal 20120101 |
| Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. | BMC pulmonary medicine 20120101 |
| Antioxidants in kidney diseases: the impact of bardoxolone methyl. | International journal of nephrology 20120101 |
| Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells. | Renal failure 20120101 |
| Current and novel drug therapies for idiopathic pulmonary fibrosis. | Drug design, development and therapy 20120101 |
| Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. | PloS one 20120101 |
| Clinical, molecular, and cellular features of non-Puerto Rican Hermansky-Pudlak syndrome patients of Hispanic descent. | The Journal of investigative dermatology 20111201 |
| [Innovative therapeutics for idiopathic pulmonary fibrosis]. | Presse medicale (Paris, France : 1983) 20111201 |
| Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. | Bioorganic & medicinal chemistry 20111201 |
| [Role of medical treatment for symptomatic leiomyoma management in premenopausal women]. | Journal de gynecologie, obstetrique et biologie de la reproduction 20111201 |
| [Treatment of pulmonary fibrosis. New substances and new interventions]. | Der Internist 20111201 |
| Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells. | Die Pharmazie 20111201 |
| Pirfenidone: in idiopathic pulmonary fibrosis. | Drugs 20110910 |
| Newer modes of treating interstitial lung disease. | Current opinion in pulmonary medicine 20110901 |
| A first step against idiopathic pulmonary fibrosis. | European respiratory review : an official journal of the European Respiratory Society 20110901 |
| Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? | European respiratory review : an official journal of the European Respiratory Society 20110901 |
| Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy. | Molecular and cellular biochemistry 20110801 |
| Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. | Expert review of respiratory medicine 20110801 |
| Pirfenidone. | Nature reviews. Drug discovery 20110701 |
| Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. | Molecular genetics and metabolism 20110601 |
| Pirfenidone for diabetic nephropathy. | Journal of the American Society of Nephrology : JASN 20110601 |
| [Interstitial lung disease]. | Deutsche medizinische Wochenschrift (1946) 20110601 |
| Trials and tribulations of new agents, novel biomarkers, and retarding renal progression. | Journal of the American Society of Nephrology : JASN 20110601 |
| Antifibrotic activities of pirfenidone in animal models. | European respiratory review : an official journal of the European Respiratory Society 20110601 |
| Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. | Lancet (London, England) 20110521 |
| Pirfenidone for idiopathic pulmonary fibrosis. | Lancet (London, England) 20110521 |
| Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery. | Investigative ophthalmology & visual science 20110516 |
| Novel therapeutic approaches for pulmonary fibrosis. | British journal of pharmacology 20110501 |
| Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data. | International urology and nephrology 20110301 |
| [The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice]. | Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 20110201 |
| Scarred by disease. | Nature medicine 20110101 |
| Pirfenidone treatment of idiopathic pulmonary fibrosis. | Therapeutics and clinical risk management 20110101 |
| A massive abdominal wall desmoid tumor occurring in a laparotomy scar: a case report. | World journal of surgical oncology 20110101 |
| A Regenerative Antioxidant Protocol of Vitamin E and α-Lipoic Acid Ameliorates Cardiovascular and Metabolic Changes in Fructose-Fed Rats. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| The protective effect of Malva sylvestris on rat kidney damaged by vanadium. | Lipids in health and disease 20110101 |
| A rare cause of interstitial lung disease: Hermansky-Pudlak syndrome. | Tuberkuloz ve toraks 20110101 |
| Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. | BMC cardiovascular disorders 20110101 |
| Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders. | Pulmonary medicine 20110101 |
| Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer. | Pulmonary medicine 20110101 |
| Antifibrotic treatment and other new strategies for improving renal outcomes. | Contributions to nephrology 20110101 |
| Decorin and colchicine as potential treatments for post-haemorrhagic ventricular dilatation in a neonatal rat model. | Neonatology 20110101 |
| The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. | Respiratory research 20110101 |
| Role of TGF-β signaling in inherited and acquired myopathies. | Skeletal muscle 20110101 |
| Pharmacokinetics of pirfenidone after topical administration in rabbit eye. | Molecular vision 20110101 |
| An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition. | Lung India : official organ of Indian Chest Society 20110101 |
| Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal. | Journal of translational medicine 20110101 |
| Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment. | Respiratory research 20110101 |
| Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. | Clinical medicine insights. Case reports 20110101 |
| In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. | PloS one 20110101 |
| Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis. | PloS one 20110101 |
| [Idiopathic pulmonary fibrosis -- progress in sight]. | Duodecim; laaketieteellinen aikakauskirja 20110101 |
| The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress. | Current cardiology reviews 20101101 |
| Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. | Heart rhythm 20101001 |
| [Pirfenidone diminishes SiO2 induced lung fibrosis in rats]. | Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 20101001 |
| Non-steroid agents for idiopathic pulmonary fibrosis. | The Cochrane database of systematic reviews 20100908 |
| Oxidative stress and antioxidants in interstitial lung disease. | Current opinion in pulmonary medicine 20100901 |
| Progress toward novel treatments for chronic kidney disease. | Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20100901 |
| [Interstitial lung diseases - historical development, current status, future prospects]. | Pneumologie (Stuttgart, Germany) 20100901 |
| Pirfenidone in idiopathic pulmonary fibrosis. | The European respiratory journal 20100901 |
| Staphylococcal enterotoxins. | Toxins 20100801 |
| Current and future treatment options in idiopathic pulmonary fibrosis. | Inflammation & allergy drug targets 20100701 |
| Regulatory watch: Surprise setback for lung fibrosis drug highlights trial challenges. | Nature reviews. Drug discovery 20100701 |
| Pirfenidone in idiopathic pulmonary fibrosis. | Drugs of today (Barcelona, Spain : 1998) 20100701 |
| Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels. | Investigative ophthalmology & visual science 20100601 |
| New pharmacological treatments for improving renal outcomes in diabetes. | Nature reviews. Nephrology 20100601 |
| Investigational approaches to therapies for idiopathic pulmonary fibrosis. | Expert opinion on investigational drugs 20100601 |
| Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. | Expert review of respiratory medicine 20100601 |
| Molecular basis and current treatment for alcoholic liver disease. | International journal of environmental research and public health 20100501 |
| Pirfenidone in idiopathic pulmonary fibrosis. | The European respiratory journal 20100401 |
| Idiopathic pulmonary fibrosis and pirfenidone. | The European respiratory journal 20100401 |
| FDA panel likes new treatment for idiopathic pulmonary fibrosis. | Managed care (Langhorne, Pa.) 20100401 |
| Renoprotective properties of pirfenidone in subtotally nephrectomized rats. | European journal of pharmacology 20100310 |
| Inhibition of matrix deposition: a new strategy for prevention of restenosis after balloon angioplasty. | Journal of cardiovascular pharmacology 20100201 |
| Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. | Expert opinion on investigational drugs 20100201 |
| Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. | PloS one 20100101 |
| Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive subjects. | Journal of biomedical science 20100101 |
| Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study. | Arthritis research & therapy 20100101 |
| Clinical use of biomarkers of survival in pulmonary fibrosis. | Respiratory research 20100101 |
| Interstitial lung diseases in children. | Orphanet journal of rare diseases 20100101 |
| Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. | Arthritis research & therapy 20100101 |
| The multifaceted role of pirfenidone and its novel targets. | Fibrogenesis & tissue repair 20100101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20100101 |
| Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study. | Cardiovascular diabetology 20100101 |
| Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease. | The open cardiovascular medicine journal 20100101 |
| Inflammatory cytokines and atrial fibrillation: current and prospective views. | Journal of inflammation research 20100101 |
| Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1. | American journal of respiratory and critical care medicine 20091201 |
| Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. | Transplantation 20091127 |
| Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells. | Clinical and experimental pharmacology & physiology 20091001 |
| Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis. | Clinical and experimental pharmacology & physiology 20091001 |
| Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells. | Nephrology (Carlton, Vic.) 20090901 |
| Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. | Transplantation 20090815 |
| Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. | Investigative ophthalmology & visual science 20090801 |
| Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. | Pulmonary pharmacology & therapeutics 20090801 |
| Pirfenidone is renoprotective in diabetic kidney disease. | Journal of the American Society of Nephrology : JASN 20090801 |
| Effects of intravenous administration of pirfenidone on horses with experimentally induced endotoxemia. | American journal of veterinary research 20090801 |
| [Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis]. | Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090801 |
| Recent advances in pharmacotherapy of atrial fibrillation. | Indian journal of pharmacology 20090801 |
| Recent advances in the treatment of systemic sclerosis. | Clinical reviews in allergy & immunology 20090601 |
| Established and newly proposed mechanisms of chronic cyclosporine nephropathy. | The Korean journal of internal medicine 20090601 |
| Advances in understanding of idiopathic pulmonary fibrosis. | Chinese medical journal 20090405 |
| Permutation test following covariate-adaptive randomization in randomized controlled trials. | Journal of biopharmaceutical statistics 20090101 |
| Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis. | Respiratory research 20090101 |
| Liver fibrosis secondary to bile duct injury: correlation of Smad7 with TGF-beta and extracellular matrix proteins. | BMC gastroenterology 20090101 |
| Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. | Radiation oncology (London, England) 20090101 |
| New developments in the therapy of pulmonary fibrosis. | Advances in pharmacology (San Diego, Calif.) 20090101 |
| The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: The results of an open prospective trial. | Lung India : official organ of Indian Chest Society 20090101 |
| Optimal treatment for idiopathic pulmonary fibrosis. | Thorax 20081201 |
| Role of TGF-beta on cardiac structural and electrical remodeling. | Vascular health and risk management 20081201 |
| Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy. | Hepatology international 20081201 |
| Current and future anti-fibrotic therapies for chronic liver disease. | Clinics in liver disease 20081101 |
| Potent antioxidant role of pirfenidone in experimental cirrhosis. | European journal of pharmacology 20081024 |
| Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. | Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20081001 |
| Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model? | Acta paediatrica (Oslo, Norway : 1992) 20080901 |
| Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. | European journal of pharmacology 20080820 |
| Superoxide scavenging activity of pirfenidone-iron complex. | Biochemical and biophysical research communications 20080718 |
| Pharmacokinetics and clinical effects of pirfenidone administered intravenously in horses. | American journal of veterinary research 20080701 |
| Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review. | European journal of internal medicine 20080601 |
| Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. | International immunopharmacology 20080501 |
| Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats. | Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080401 |
| Pharmacokinetics and metabolism of intravenous pirfenidone in sheep. | Biopharmaceutics & drug disposition 20080301 |
| Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts. | Life sciences 20080116 |
| Pirfenidone prevents capsular contracture after mammary implantation. | Aesthetic plastic surgery 20080101 |
| The role of aldosterone blockade in murine lupus nephritis. | Arthritis research & therapy 20080101 |
| Idiopathic pulmonary fibrosis. | Orphanet journal of rare diseases 20080101 |
| Aggressive juvenile fibromatosis of the paranasal sinuses: case report and brief review. | Journal of hematology & oncology 20080101 |
| p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis. | Experimental and molecular pathology 20071201 |
| Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. | Journal of clinical pharmacology 20071001 |
| Do we have a pill for renal fibrosis? | Clinical journal of the American Society of Nephrology : CJASN 20070901 |
| Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. | Clinical journal of the American Society of Nephrology : CJASN 20070901 |
| Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection. | Transplantation proceedings 20070901 |
| Novel oral agents for multiple sclerosis. | Current neurology and neuroscience reports 20070501 |
| Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas. | Pediatric neurology 20070501 |
| Idiopathic pulmonary fibrosis. | The Journal of the Association of Physicians of India 20070501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20070401 |
| Pirfenidone inhibits TGF-beta expression in malignant glioma cells. | Biochemical and biophysical research communications 20070309 |
| A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone. | Muscle & nerve 20070201 |
| Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma. | Pulmonary pharmacology & therapeutics 20070101 |
| The role of PDGF in radiation oncology. | Radiation oncology (London, England) 20070101 |
| Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. | PloS one 20070101 |
| Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. | Radiation oncology (London, England) 20070101 |
| Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. | Comparative hepatology 20070101 |
| Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases. | Drug target insights 20070101 |
| Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography. | Biomedical chromatography : BMC 20061201 |
| Phase II trial of pirfenidone in adults with neurofibromatosis type 1. | Neurology 20061128 |
| A pilot study in patients with established advanced liver fibrosis using pirfenidone. | Gut 20061101 |
| Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. | Circulation 20061017 |
| Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. | American journal of respiratory cell and molecular biology 20060901 |
| Long-term administration of pirfenidone improves cardiac function in mdx mice. | Muscle & nerve 20060901 |
| Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. | Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20060901 |
| Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis. | Archiv der Pharmazie 20060801 |
| Pirfenidone for the treatment of idiopathic pulmonary fibrosis. | Expert opinion on investigational drugs 20060701 |
| [Newly developed therapeutic drugs for idiopathic interstitial pneumonias]. | Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060610 |
| Promising pharmacologic innovations in treating pulmonary fibrosis. | Current opinion in pharmacology 20060601 |
| Current perspectives on the treatment of idiopathic pulmonary fibrosis. | Proceedings of the American Thoracic Society 20060601 |
| Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients. | European journal of pharmacology 20060501 |
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| [Pulmonary fibrosis--a therapeutic dilemma?]. | Medizinische Klinik (Munich, Germany : 1983) 20060415 |
| Pirfenidone and chronic progressive obliterative airway disease. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20060401 |
| Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach. | Clinics in chest medicine 20060301 |
| EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts. | Respiratory research 20060101 |
| Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review. | Respiration; international review of thoracic diseases 20060101 |
| Sequential testing for efficacy in clinical trials with non-transient effects. | Statistics in medicine 20051115 |
| Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF. | American journal of respiratory and critical care medicine 20051101 |
| The questionable efficacy of pirfenidone in IPF. | American journal of respiratory and critical care medicine 20051101 |
| Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. | Expert opinion on investigational drugs 20051101 |
| Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts. | The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20051001 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20051001 |
| Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model. | The Journal of thoracic and cardiovascular surgery 20050901 |
| Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050601 |
| Treatment of idiopathic pulmonary fibrosis: is there anything new? | Respirology (Carlton, Vic.) 20050601 |
| [Drug treatments for idiopathic pulmonary fibrosis]. | Revue de pneumologie clinique 20050601 |
| The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. | The Journal of surgical research 20050515 |
| Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. | American journal of respiratory and critical care medicine 20050501 |
| Is idiopathic pulmonary fibrosis now treatable? | American journal of respiratory and critical care medicine 20050501 |
| [Interstitial pneumonia]. | Nihon rinsho. Japanese journal of clinical medicine 20050501 |
| Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats. | The Journal of pharmacology and experimental therapeutics 20050401 |
| A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. | Multiple sclerosis (Houndmills, Basingstoke, England) 20050401 |
| Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity. | Transplantation 20050227 |
| Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. | Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050101 |
| Retardation of kidney failure -- applying principles to practice. | Annals of the Academy of Medicine, Singapore 20050101 |
| [Expectation of new treatments for idiopathic interstitial pneumonias]. | Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050101 |
| The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model. | Transplantation proceedings 20050101 |
| Primary progressive multiple sclerosis : current and future treatment options. | CNS drugs 20050101 |
| Expression of HSP47 in usual interstitial pneumonia and nonspecific interstitial pneumonia. | Respiratory research 20050101 |
| Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada. | Reviews in neurological diseases 20050101 |
| Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a double-blind and acute and chronic lameness of musculoskeletal origin in an open multi-centered field trial in horses. | Research communications in molecular pathology and pharmacology 20050101 |
| Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy. | Current diabetes reports 20041201 |
| Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes. | Journal of hepatology 20041101 |
| The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. | Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20041101 |
| Pharmacokinetics of orally administered pirfenidone in male and female beagles. | Journal of veterinary pharmacology and therapeutics 20041001 |
| Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats. | Transplantation proceedings 20040901 |
| Effects of pirfenidone on endotoxin-induced liver injury after partial hepatectomy in rats. | Transplantation proceedings 20040901 |
| Effect of pirfenidone on induction of chemokines in rat hepatocytes. | Transplantation proceedings 20040901 |
| Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. | Expert opinion on pharmacotherapy 20040801 |
| Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. | The European respiratory journal 20040701 |
| Potential nonhormonal therapeutics for medical treatment of leiomyomas. | Seminars in reproductive medicine 20040501 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20040501 |
| Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model. | Transplantation 20040315 |
| New perspectives in treatment of glomerulonephritis. | Pediatric nephrology (Berlin, Germany) 20040301 |
| Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. | Cancer chemotherapy and pharmacology 20040201 |
| Pirfenidone. | IDrugs : the investigational drugs journal 20040201 |
| Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. | Journal of hepatology 20040101 |
| Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. | Drugs 20040101 |
| Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents. | Journal of nephrology 20040101 |
| Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans. | Research communications in molecular pathology and pharmacology 20040101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20031201 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20031101 |
| Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity. | Toxicological sciences : an official journal of the Society of Toxicology 20030901 |
| Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone. | The American journal of gastroenterology 20030801 |
| Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse. | Journal of Korean medical science 20030801 |
| Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis. | Multiple sclerosis (Houndmills, Basingstoke, England) 20030601 |
| Inhibition of experimental acute pulmonary inflammation by pirfenidone. | Pulmonary pharmacology & therapeutics 20030101 |
| Modulation of articular chondrocyte activity by pirfenidone. | Research communications in molecular pathology and pharmacology 20030101 |
| Pirfenidone effectively reverses experimental liver fibrosis. | Journal of hepatology 20021201 |
| Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis. | Internal medicine (Tokyo, Japan) 20021201 |
| Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine. | Clinical and experimental pharmacology & physiology 20021101 |
| Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. | Journal of hepatology 20021101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021101 |
| [Treatment of pulmonary fibrosis]. | Presse medicale (Paris, France : 1983) 20021019 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20021001 |
| From anti-inflammatory drugs through antifibrotic agents to lung transplantation: a long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis. | Chest 20020901 |
| Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. | Biochemical pharmacology 20020801 |
| Pirfenidone inhibits early neointimal proliferation following arterial injury. | Transplantation proceedings 20020801 |
| Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration. | Biopharmaceutics & drug disposition 20020701 |
| Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. | Molecular genetics and metabolism 20020701 |
| Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. | European journal of pharmacology 20020620 |
| A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. | European journal of pharmacology 20020620 |
| Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. | Infection and immunity 20020601 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats. | European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20020301 |
| Retinoic acid exacerbates experimental radiation nephropathy. | Radiation research 20020201 |
| Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. | British journal of pharmacology 20020201 |
| Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20020201 |
| Growth factors in idiopathic pulmonary fibrosis: relative roles. | Respiratory research 20020101 |
| Pirfenidone in the treatment of primary sclerosing cholangitis. | Digestive diseases and sciences 20020101 |
| Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection. | Pulmonary pharmacology & therapeutics 20020101 |
| Idiopathic pulmonary fibrosis: current and future treatment options. | American journal of respiratory medicine : drugs, devices, and other interventions 20020101 |
| Antifibrotic therapy for the treatment of pulmonary fibrosis. | The American journal of the medical sciences 20011001 |
| Pirfenidone for chronic progressive multiple sclerosis. | Multiple sclerosis (Houndmills, Basingstoke, England) 20011001 |
| Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice. | European journal of pharmacology 20010824 |
| Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. | Clinical and experimental pharmacology & physiology 20010701 |
| Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats. | British journal of pharmacology 20010701 |
| A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia. | British journal of haematology 20010701 |
| The balance between collagen synthesis and degradation in diffuse lung disease. | Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 20010301 |
| Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury. | Transplantation proceedings 20010101 |
| Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. | Journal of nephrology 20010101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.